STAT+: Lilly wins approval for once-weekly insulin shot

AI Summary

The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, providing an alternative to daily long-acting insulin injections and potentially improving patient compliance. This marks a significant advancement in diabetes treatment options.

The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.